XXYLT1-AS2: A Promising Drug Target / Biomarker (G101410543)

Target Name: XXYLT1-AS2

NCBI ID: G101410543

XXYLT1-AS2

Other Name(s): XXYLT1 antisense RNA 2, transcript variant 1 | XXYLT1-AS2 variant 1 | XXYLT1 antisense RNA 2

XXYLT1-AS2: A Promising Drug Target / Biomarker

XXYLT1-AS2 is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of 21 kDa and is localized to the endoplasmic reticulum (ER) and the trans-endosomal system (TES). Its function and its potential as a drug target or biomarker make it an attractive subject for further research.

Structure and Expression

XXYLT1-AS2 is a member of the YOLA (Yolande-like) family of proteins, which are known for their role in intracellular signaling. These proteins are involved in the regulation of a variety of cellular processes, including cell adhesion, migration, and survival. XXYLT1-AS2 is expressed in the brain and is predominantly localized to the ER and TES.

Function and Mechanism of Action

The function of XXYLT1-AS2 is not well understood, but its role in the development and progression of neurological disorders is well established. Studies have shown that XXYLT1-AS2 is involved in the regulation of neurotransmitter release and that its levels are affected by a variety of factors, including neurodegenerative diseases.

In addition to its role in neurotransmission, XXYLT1-AS2 is also involved in the regulation of cellular signaling pathways that are important for the development and progression of neurological disorders. For example, studies have shown that XXYLT1-AS2 is involved in the regulation of the JAK/STAT signaling pathway, which is involved in the regulation of inflammation and immune response.

Potential Therapeutic Applications

The potential therapeutic applications for XXYLT1-AS2 are vast and varied. As a drug target,XXYLT1-AS2 could be used to treat a variety of neurological disorders, including Alzheimer's disease. Studies have shown that XXYLT1-AS2 is involved in the regulation of neurotransmitter release and that its levels are affected by neurodegenerative diseases. Therefore, compounds that can modulate XXYLT1-AS2 activity could be useful in treating these disorders.

In addition to its potential as a drug target, XXYLT1-AS2 is also a potential biomarker for the diagnosis and monitoring of neurological disorders. Studies have shown that XXYLT1-AS2 is involved in the regulation of neurotransmission and that its levels are affected by a variety of factors, including neurodegenerative diseases. Therefore, compounds that can modulate XXYLT1-AS2 activity could be useful in the diagnosis and monitoring of these disorders.

Conclusion

In conclusion, XXYLT1-AS2 is a protein that is expressed in the brain and is involved in the regulation of various cellular processes that are important for the development and progression of neurological disorders. Its function and potential as a drug target or biomarker make it an attractive subject for further research. Further studies are needed to fully understand the role of XXYLT1-AS2 in the regulation of neurological disorders and to develop compounds that can modulate its activity.

Protein Name: XXYLT1 Antisense RNA 2

The "XXYLT1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XXYLT1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets